



**PATENT**  
Attorney Docket No. MEE-002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): *Miller et al.*

SERIAL NO.: 09/780,142 GROUP NO.: 1644

FILING DATE: February 9, 2001 EXAMINER: Huynh, Phuong N.

TITLE: METHODS AND COMPOSITIONS FOR TREATING CONDITIONS  
OF THE EYE

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed. In addition, Applicants wish to inform the Examiner about the following U.S. patents and patent applications and the content of their file wrappers, including all Office actions issued therein:

1. U.S. Patent Application Serial No. 10/429,496 filed on May 5, 2003, and published as 2003/0175282, on September 18, 2003 (Ref. A17); and
2. U.S. Patent Application Serial No. 10/429,428, filed on May 5, 2003, and published as 2003/0185834, on October 2, 2003 (Ref A18).

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- the requisite Statement is below, **OR**
- the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- the requisite Statement is below, **AND**
- the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.


#### STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R.

**1.56(c) more than three months prior to the filing of the Information Disclosure Statement.**

Respectfully submitted,



---

Daniel A. Wilson  
Attorney for Applicant(s)  
Goodwin Procter LLP  
Exchange Place  
Boston, Massachusetts 02109  
Customer No. 051414

Date: September 19, 2005  
Reg. No. 45,508

Tel. No.: (617) 570-1809  
Fax No.: (617) 523-1231

<b>COURTESY FORM PTO - 1449</b> <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>					<b>ATTORNEY DOCKET NO.: MEE-002</b> <b>APPLICANTS:</b> Miller <i>et al.</i> <b>SERIAL NO.:</b> 09/780,142 <b>FILING DATE:</b> February 9, 2001 <b>EXAMINER:</b> Huynh, P. <b>GROUP:</b> 1644				
<b>U.S. PATENT DOCUMENTS</b>									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<b>OTHER ART, JOURNAL ARTICLES, ETC.</b>									
EXAM. INIT.	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>								
	C133	Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab V2, an Anti-vascular Endothelial Growth Factor (VEGF) Antibody Fragment, in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," <u>ARVO Poster</u> , May 2002.							
	C134	Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab VEGF in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," <u>ARVO, The Association for Research in Vision and Ophthalmology</u> (Oasis, Online Abstract Submission and Invention System, Program Planner, Presentation # 566), May 2002.							
	C138	Heier <i>et al.</i> , "rhuFAB V2 (an Anti-VEGF Antibody Fragment) in Neovascular AMD: Safety and Tolerability of Multiple Intravitreal Injections - Preliminary Data from a Single Center," <u>ARVO Poster</u> , May 2002.							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

FORM PTO - 1449  SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT 		ATTORNEY DOCKET NO.: MEE-002  APPLICANTS: Miller <i>et al.</i>  SERIAL NO.: 09/780,142  FILING DATE: February 9, 2001  EXAMINER: Huynh, P. GROUP: 1644	
--	--	--	--

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A14	5,171,749	12/15/92	Levy <i>et al.</i>	514	410	06/20/91
	A15	6,162,242	12/19/00	Peyman	607	88	01/21/99
	A16	6,899,723	05/31/05	Chen	607	88	07/13/01
	A17	2003-0175282	09/18/03	Miller <i>et al.</i>	424	133	05/05/03
	A18	2003-0185834	10/02/03	Miller <i>et al.</i>	424	133	05/05/03

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C170	Blaauwgeers <i>et al.</i> , "Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris," Am. J. Pathology 155(2): 421-428, 1999.
	C171	Husain <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Experimental Choroidal Neovascularization in the Monkey," Arch Ophthalmol, 123: 509-516, 2005.
	C172	Witte <i>et al.</i> , "Monoclonal antibodies targeting the VEGF receptor-2 (Flk/KDR) as an anti-angiogenic therapeutic strategy," Cancer and Metastasis Reviews 17: 155-161, 1998.

EXAMINER	DATE CONSIDERED
LIBC/2598347.1	